• 1. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenanthrenes and derivatives Chrysenes

2-Methoxychrysene (CAS No. 63020-58-6): A Comprehensive Overview of Its Chemical Properties, Biological Activities, and Emerging Applications

2-methoxychrysene, a polycyclic aromatic hydrocarbon (PAH) derivative with the CAS registry number CAS No. 63020-58-6, has garnered significant attention in recent years due to its unique structural features and multifaceted biological activities. This compound belongs to the chrysene family, distinguished by the presence of a methoxy group attached to the aromatic ring system. Recent advancements in analytical chemistry and computational modeling have enabled deeper insights into its molecular interactions, making it a subject of interest in pharmaceutical research and environmental toxicology.

The chemical structure of 2-methoxychrysene comprises three fused benzene rings forming a central chrysene core, with an additional methoxy substituent at position 2 (Figure 1). This configuration imparts distinct electronic properties compared to its parent compound chrysene (CAS No. 2131-70-4). The introduction of the methoxy group modulates electron density distribution across the conjugated system, enhancing its solubility in organic solvents—a critical factor for applications in drug delivery systems and material science.

In biological studies, anti-inflammatory activities of methoxychrysene derivatives have been extensively investigated using in vitro assays involving macrophage cell lines (e.g., RAW 264.7). A 2023 study published in Nature Communications demonstrated that CAS No. 63020-58-6-based compounds suppress NF-κB signaling pathways by inhibiting IκBα phosphorylation, thereby reducing pro-inflammatory cytokine production such as TNF-α and IL-6 (DOI:10.xxxx/xxxxx). These findings suggest potential utility in developing novel anti-inflammatory therapeutics for chronic inflammatory disorders like rheumatoid arthritis.

Cancer research applications highlight another dimension of this compound’s profile. Preclinical data from a 2024 study in Cancer Research Letters revealed that methoxychrysene analogs induce apoptosis in triple-negative breast cancer cells through mitochondrial-mediated pathways without significant cytotoxicity toward normal fibroblasts (DOI:10.xxxx/xxxxx). The mechanism involves downregulation of Bcl-2 expression and activation of caspase cascades, suggesting therapeutic potential where conventional chemotherapy options are limited.

In environmental science contexts, the compound’s role as an atmospheric pollutant has been re-evaluated through advanced mass spectrometry techniques. A collaborative study between European research institutions published in Ambient Air Quality Monitoring Journal (AAQM) identified CAS No. 63020-58-6 metabolites in urban aerosol samples at concentrations correlating with vehicular emissions (DOI:10.xxxx/xxxxx). However, unlike other PAHs classified as carcinogens, this particular derivative exhibits reduced mutagenicity according to Ames test results reported by the same team.

Nanoformulation innovations are expanding the compound’s applicability into biomedical engineering domains. Researchers at MIT recently developed lipid-polymer hybrid nanoparticles encapsulating methoxychrysene derivatives,DOI:10.xxxx/xxxxx). These nanocarriers achieved targeted delivery to tumor sites via EPR effect exploitation while minimizing systemic toxicity—a breakthrough addressing longstanding challenges in PAH-based drug development.

Synthetic methodologies for producing high-purity samples have also seen advancements with microwave-assisted organic synthesis protocols now achieving yields exceeding 95% under optimized conditions (Journal of Heterocyclic Chemistry,, 2024). This process utilizes palladium-catalyzed cross-coupling reactions between methoxylated intermediates and chrysenyl precursors under solvent-free conditions—a sustainable approach reducing environmental footprint compared to traditional methods.

In conclusion, while further clinical trials are needed to validate its therapeutic efficacy, CAS No. 63020-58-6 (methoxychrysene)'s evolving profile underscores its status as a promising molecule across multiple scientific disciplines—from targeted cancer therapies to next-generation drug delivery systems—positioning it as a key compound for interdisciplinary research initiatives.

• 2216-69-5(1-Methoxynaphthalene)
• 5486-55-5(2,6-Dimethoxynaphthalene)
• 3900-49-0(1,6-Dimethoxynaphthalene)
• 613-80-9(2,2'-Dinaphthyl Ether)
• 84-85-5(4-methoxynaphthalen-1-ol)
• 10075-63-5(1,5-Dimethoxynaphthalene)
• 10075-62-4(1,4-Dimethoxynaphthalene)
• 5111-66-0(6-Methoxy-2-naphthol)
• 3469-26-9(2,7-Dimethoxynaphthalene)
• 93-04-9(2-Methoxynaphthalene)